Bioceltix is ​​initiating the registration process for a drug for equine arthritis. The company has submitted an application to the European Medicines Agency.

Another important milestone in the history of Bioceltix. The publicly traded veterinary company has submitted an application to the European Medicines Agency (EMA) for a positive recommendation for the stem cell-based drug BCX-EM for equine arthritis. The excellent results from the product’s clinical trial confirmed its efficacy and safety. The drug’s therapeutic effect persists even […]